Previously, we showed that LNK-754, an FTI tested in cancer trials, enhanced lysosomal hydrolase trafficking, and decreased alpha-synuclein (α-synuclein) aggregates in Parkinson’s disease (PD) patient-derived neurons and PD mouse models [8]. This evidence concerns the gene SNCA and cancer.